Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

NCT06959615 is registered in ClinicalTrials.gov with Jacobio Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT06959615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06959615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 22, 2024
Completion date
August 31, 2027
Enrollment
334 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor